Intermediate-Sized Expanded Access Study
- Conditions
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Seelos Therapeutics, Inc.
- Registration Number
- NCT05597436
- Locations
- ๐บ๐ธ
Hospital for Special Care, New Britain, Connecticut, United States
๐บ๐ธHoly Cross Hospital - Phil Smith Neuroscience Institute, Fort Lauderdale, Florida, United States
๐บ๐ธNova Southeastern University, Fort Lauderdale, Florida, United States
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Seelos Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05490563
- Locations
- ๐บ๐ธ
Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
๐ฐ๐ทKorea University Guro Hospital, Seoul, Korea, Republic of
๐ฉ๐ชUniversity Hospital of Leipzig, Leipzig, Saxonia, Germany
SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Seelos Therapeutics, Inc.
- Registration Number
- NCT05332678
- Locations
- ๐ฆ๐บ
Neurodegenerative Disorders Research Pty Ltd, West Perth, Western Australia, Australia
๐ฆ๐บAustin Health, Heidelberg, Victoria, Australia
๐ฆ๐บGoulburn Valley Health, Shepparton, Victoria, Australia
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Seelos Therapeutics, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT04669665
- Locations
- ๐บ๐ธ
Seelos Investigational Site, Morgantown, West Virginia, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath